AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05139511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
Study NCT05139511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Same procedure but without energy
Study NCT04658940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQBlate® Force Sensing Ablation System
Description: Percutaneous catheter ablation of the cavotricuspid isthmus
Study NCT06544291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 600mg
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
Study NCT06544291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 600mg
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
Study NCT06544291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 0mg
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
Study NCT06544291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0mg
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
Study NCT06227182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound with surface electromyography and dynamometry
Description: The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
Study NCT06227182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
Study NCT05424783 — intervention group
Intervention type: OTHER
Intervention: Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Description: The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
Study NCT06240364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron extract (Crocus sativus)
Description: Daily intake of one tablet for 84 days.
Study NCT06240364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of one tablet for 84 days.
Study NCT06271525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cupping therapy
Description: All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~1. -Primary sucking~2. -Scarification 3- Bloodletting 4-Removal~5 -Dressing
Study NCT05231837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Fee Waiver
Description: Fees are waived for youth sports programs at the park and recreation center
Study NCT05231837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fee Waiver Plus Intensive Outreach
Description: Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
Study NCT05218798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardio Respiratory Fitness testing
Description: In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial
Study NCT05454553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myocardial perfusion SPECT
Description: For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)
Study NCT06344624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT group
Description: Brief cognitive behavioral therapy
Study NCT06344624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Laughter group
Description: Laughter yoga therapy
Study NCT05606562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental care
Description: Participants will be offered free dental care
Study NCT05843279 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myofunctional therapy
Description: In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
Study NCT05843279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy
Description: In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
Study NCT04195776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study NCT05355493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time to Exhaustion cycling test
Description: After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
Study NCT05355493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time to Exhaustion cycling test
Description: After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
Study NCT05355493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go/NoGo task
Description: Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
Study NCT05355493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go/NoGo task
Description: Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
Study NCT06327022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social media-based electronic bibliotherapy
Description: Eight weekly sessions of bibliotherapy are delivered via their daily social media.
Study NCT06327022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The routine services provided by community centers
Study NCT06401629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NPRP criteria
Description: Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, >6.8 to ≤7.5, >7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
Study NCT06401629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IADPSG criteria
Description: The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
Study NCT05229497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days
Study NCT05229497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days
Study NCT05466643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 0.3mg
Description: 1 tablet, Orally, Once daily single dose
Study NCT05466643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP16001 Placebo
Description: 1 tablet, Orally, Once daily single dose
Study NCT06296563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-hepatic artery infusion for 2 times.
Study NCT06296563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
Study NCT06296563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, po, qd,q3w,up to one year of use at most.
Study NCT05229497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion,Specified dose on specified days
Study NCT05229497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion,Specified dose on specified days
Study NCT05229497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV infusion,Specified dose on specified days
Study NCT06149247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
Study NCT06149247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechlorethamine Topical Gel
Description: Valchlor is an FDA-approved drug for the treatment of CTCL.
Study NCT06290440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepharmacy-led counselling
Description: The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
Study NCT06290440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led counselling
Description: Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
Study NCT06055166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
Description: Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
Study NCT04075435 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: high CBD/low THC sublingual solution
Description: Hemp derived solution to be administered sublingually twice daily.
Study NCT06381830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.
Study NCT06381830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.
Study NCT06381830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Therapy
Description: CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
Study NCT06127329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAI combine with DEB-BACE
Description: 1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery.
Study NCT05728814 — intervention group
Intervention type: DRUG
Intervention: Dostarlimab
Description: The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles.
Study NCT05808036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention: DOMINO app
Description: Life style intervention and diet low in FODMAPs.
Study NCT05808036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: DOMINO app
Description: Life style intervention and diet low in FODMAPs.
Study NCT05808036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: low FODMAP diet
Description: Strict low FODMAP diet.
Study NCT04818515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral; Tablet
Study NCT04818515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral; Tablet
Study NCT04793399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 MG Monotherapy
Description: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
Study NCT04793399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
Description: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Study NCT06412692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Motivational Interviewing Technique
Description: Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
Study NCT05077696 — intervention group
Intervention type: OTHER
Intervention: Drawing a tube of blood (serum)
Description: dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
Study NCT01352663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wockhardt's Insulin Analogue (Recomb)
Description: Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
Study NCT01352663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
Study NCT06430437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
Study NCT06430437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Description: Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)
Study NCT05151588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Study NCT05151588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Study NCT05151588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
Study NCT05151588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
Study NCT05151588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery
Study NCT05151588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemoradiation as either radical treatment or post-operative treatment after surgery